Francis Medical is developing novel, disruptive therapeutic solutions to treat prostate, kidney and bladder cancer.*
Francis Medical is a dynamic medical device company committed to developing urological cancer treatments that are tough on cancer, yet gentle on patients. Our work is fueled by a compassionate belief that cancer can be stopped with minimally invasive treatments.
Initially, Francis Medical is focusing its efforts on prostate cancer, the second most common cancer in American men that often includes treatments with undesired side effects like urinary incontinence and erectile dysfunction.
Francis Medical is named after Francis Hoey, the father of inventor and Francis Medical founder, Michael Hoey. In 1991, after undergoing prostate cancer treatments with debilitating effects on his daily living, Francis died from prostate cancer.
Today, the work of Francis Medical stands as a tribute to and a lasting legacy of Francis Hoey.
Cancer Ablation by Water Vapor
Water vapor technology, a new platform being explored for treating a variety of endourological cancers, uses the energy stored in a few drops of water to ablate cancerous tissue. This new therapy is designed to not only ablate cancer cells but also protect surrounding structures, lessening the likelihood of the life-altering side effects common with other cancer treatments.
Water Vapor Technology
Although this novel approach is being designed to address a variety of endourological cancers, initial efforts are focused on the treatment of prostate cancer.
Water vapor technology is designed to deliver to cancerous prostate tissue the thermal energy stored in sterile water vapor. A targeted and precise application of thermal energy is administered during a simple, transurethral procedure.
Traditional prostate cancer treatments include surgery, hospital stays, and debilitating side effects such as incontinence and sexual dysfunction. In contrast, patients treated with water vapor technology should typically be able to go home the same day and resume their normal lifestyle the very next day.
A Technology Unlike Any Other
“We foresee this technology as a true minimally invasive breakthrough that will improve quality of life and expand the cancer treatment options available today for patients suffering from prostate, bladder and kidney cancers.”
– Founder and Chief Technology Officer, Michael Hoey
*Device is not commercially available and is currently being studied under an Investigational Device Exemption (IDE).
“This technology has the potential to be transformational in the management of patients with localized prostate cancer by allowing them to avoid the potentially life-altering side effects of current cancer therapies.”
DR JONATHAN JAROW, CHIEF MEDICAL OFFICER